Company Information
- Type:
- Company
- Country:
- United States of America
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 09 December 2010 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2024
Financial Information
Non-Financial Information
Engagements
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 18-Dec-2023 | 2023 Communication on Progress | Submitted |
| 03-Dec-2022 | Bristol Myers Squibb 2022 Communication on Progress | Advanced |
| 02-Dec-2021 | Bristol Myers Squibb 2021 Communication on Progress | Advanced |
| 02-Dec-2020 | Communication on Progress | Advanced |
| 02-Dec-2019 | Bristol-Myers Squibb 2019 Communication on Progress | Advanced |
| 02-Dec-2018 | 2018 Bristol-Myers Squibb Communication on Progress | Advanced |
| 02-Dec-2017 | 2017 Communication on Progress | Active |
| 02-Dec-2016 | Communication on Progress | Active |
| 03-Dec-2015 | 2015 Communication on Progress | Active |
| 03-Dec-2014 | 2014 Communication on Progress | Active |
| 03-Dec-2013 | 2013 Communication on Progress | Active |
| 04-Dec-2012 | 2012 Communication on Progress | Active |
| 05-Dec-2011 | 2011 Communication on Progress | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.